Drug Interactions with Fibrates

Fibrate-Statin Interactions

The American Heart Association recommends that when combining fibrates with statins, fenofibrate or fenofibric acid is strongly preferred over gemfibrozil because gemfibrozil causes dangerous pharmacokinetic interactions that dramatically increase the risk of rhabdomyolysis, while fenofibrate does not significantly interact with statin metabolism 1
Gemfibrozil is contraindicated with simvastatin and should be avoided with lovastatin and pravastatin due to potentially life-threatening muscle toxicity 1, 2
The mechanism involves gemfibrozil and its glucuronide metabolite acting as potent irreversible inhibitors of CYP2C8 and hepatic uptake transporters (OATP1B1/3), dramatically increasing statin blood levels 3
FDA Adverse Event Reporting System data shows rhabdomyolysis rates are approximately 15 times higher with gemfibrozil compared to fenofibrate when combined with statins (8.6 vs 0.58 per million prescriptions) 2
Specific gemfibrozil-statin restrictions:
Fenofibrate or fenofibric acid can be combined with any statin when clinically indicated, as this combination does not cause clinically significant pharmacokinetic interactions 1, 2
Large clinical trials support safety: FIELD study (n=9,795) showed zero cases of rhabdomyolysis with fenofibrate-statin combination 2
Clinical indications for fenofibrate-statin combination include triglycerides ≥500 mg/dL requiring aggressive lowering 1

Patients at higher risk for fibrate-related adverse effects include those with age >80 years, chronic kidney disease, small body frame/frailty, hypothyroidism, and multiple concurrent medications (polypharmacy) 4, 5, 6
Consider withholding fibrates (especially when combined with statins) during hospitalization for major surgery or serious illness due to substantially increased myopathy risk in these settings 5, 6